Merit Medical Systems has acquired View Point Medical, manufacturer of the OneMark Detection Imaging System and OneMark Tissue Markers, in a transaction valued at approximately $140 million.
Under terms of the deal, Merit paid $90 million in cash at closing, with two deferred payments of $25 million each due on the first and second anniversaries of the closing date, the company said.
OneMark has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). It employs ultrasound-enhanced tissue markers designed to be visible across commonly used imaging modalities to localize breast and soft tissue tumors at the time of biopsy, according to Merit. The acquisition complements Merit's existing SCOUT platform, a wire-free, nonradioactive breast localization system that uses radar technology.
Merit said the combination of the two platforms gives physicians more localization options during the initial diagnostic biopsy, potentially reducing the need for a separate pre-surgical marking procedure.
